Form 4: Twist Bioscience CFO Sells Shares Under 10b5-1 Plan

Twist Bioscience CFO Adam Laponis sold shares, including a portion for tax obligations, as disclosed in a recent Form 4 filing.

Summary

• Adam Laponis, Chief Financial Officer of Twist Bioscience Corp (TWST), reported two sales of common stock.
• On October 8, 2025, Mr. Laponis sold 3,000 shares of common stock at a price of $31.15 per share.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2025.
• On October 9, 2025, an additional 2,517 shares of common stock were sold at a price of $32.922 per share.
• This second sale was mandated to cover tax withholding obligations related to the vesting of Restricted Stock Units and was not a discretionary trade.
• Following these transactions, Mr. Laponis beneficially owns 91,525 shares of Twist Bioscience common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be perceived negatively, the explicit explanations that the sales were either pre-planned under a 10b5-1 plan or mandated for tax withholding purposes mitigate any negative implications regarding management's confidence in the company. These are routine, non-discretionary transactions.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, demonstrating structured and compliant insider trading practices.
• One sale was explicitly for tax withholding obligations, indicating a non-discretionary transaction rather than a reflection of management's outlook on the company.

Management Comments

• The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2025.
• The sale of 2,517 shares represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.

Industry Context

This Form 4 filing details routine insider transactions for a Chief Financial Officer, which are common across publicly traded companies, particularly when executives utilize Rule 10b5-1 plans for pre-scheduled stock sales or when shares are sold to cover tax liabilities from equity compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as the sales are explained as non-discretionary or pre-planned, not signaling a change in company outlook.
• Employees: No direct impact mentioned.

Key Dates

Keywords

Twist Bioscience, TWST, Adam Laponis, CFO, Insider Trading, Form 4, 10b5-1 Plan, Stock Sale, Restricted Stock Units, Tax Withholding